BIOMAT Database Logo BIOMAT Database Logo

HIV nucleoside reverse transcriptase inhibitors. 2022

Franck Amblard, and Dharmeshkumar Patel, and Eleftherios Michailidis, and Steven J Coats, and Mahesh Kasthuri, and Nicolas Biteau, and Zahira Tber, and Maryam Ehteshami, and Raymond F Schinazi
Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, 1760 Haygood Drive, Atlanta, GA, 30322, USA.

More than 40 years into the pandemic, HIV remains a global burden and as of now, there is no cure in sight. Fortunately, highly active antiretroviral therapy (HAART) has been developed to manage and suppress HIV infection. Combinations of two to three drugs targeting key viral proteins, including compounds inhibiting HIV reverse transcriptase (RT), have become the cornerstone of HIV treatment. This review discusses nucleoside reverse transcriptase inhibitors (NRTIs), including chain terminators, delayed chain terminators, nucleoside reverse transcriptase translocation inhibitors (NRTTIs), and nucleotide competing RT inhibitors (NcRTIs); focusing on their history, mechanism of action, resistance, and current clinical application, including long-acting regimens.

UI MeSH Term Description Entries
D009705 Nucleosides Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed) Nucleoside,Nucleoside Analog,Nucleoside Analogs,Analog, Nucleoside,Analogs, Nucleoside
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D023241 Antiretroviral Therapy, Highly Active Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor. Combination Antiretroviral Therapy,HAART,Highly Active Antiretroviral Therapy,Antiretroviral Therapies, Combination,Antiretroviral Therapy, Combination,Combination Antiretroviral Therapies,Therapies, Combination Antiretroviral,Therapy, Combination Antiretroviral
D024882 Drug Resistance, Viral The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation. Antiviral Drug Resistance,Antiviral Drug Resistances,Drug Resistances, Viral

Related Publications

Franck Amblard, and Dharmeshkumar Patel, and Eleftherios Michailidis, and Steven J Coats, and Mahesh Kasthuri, and Nicolas Biteau, and Zahira Tber, and Maryam Ehteshami, and Raymond F Schinazi
Nucleoside reverse transcriptase inhibitors and HIV mutagenesis.
October 2003, The Journal of antimicrobial chemotherapy,
Franck Amblard, and Dharmeshkumar Patel, and Eleftherios Michailidis, and Steven J Coats, and Mahesh Kasthuri, and Nicolas Biteau, and Zahira Tber, and Maryam Ehteshami, and Raymond F Schinazi
[HIV resistance to non-nucleoside reverse transcriptase inhibitors].
August 2006, Virologie (Montrouge, France),
Franck Amblard, and Dharmeshkumar Patel, and Eleftherios Michailidis, and Steven J Coats, and Mahesh Kasthuri, and Nicolas Biteau, and Zahira Tber, and Maryam Ehteshami, and Raymond F Schinazi
Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
February 2006, Current opinion in investigational drugs (London, England : 2000),
Franck Amblard, and Dharmeshkumar Patel, and Eleftherios Michailidis, and Steven J Coats, and Mahesh Kasthuri, and Nicolas Biteau, and Zahira Tber, and Maryam Ehteshami, and Raymond F Schinazi
[Progress in HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
August 2004, Yao xue xue bao = Acta pharmaceutica Sinica,
Franck Amblard, and Dharmeshkumar Patel, and Eleftherios Michailidis, and Steven J Coats, and Mahesh Kasthuri, and Nicolas Biteau, and Zahira Tber, and Maryam Ehteshami, and Raymond F Schinazi
Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.
December 2013, Future medicinal chemistry,
Franck Amblard, and Dharmeshkumar Patel, and Eleftherios Michailidis, and Steven J Coats, and Mahesh Kasthuri, and Nicolas Biteau, and Zahira Tber, and Maryam Ehteshami, and Raymond F Schinazi
[Non-nucleoside reverse transcriptase inhibitors].
June 2000, Annales de medecine interne,
Franck Amblard, and Dharmeshkumar Patel, and Eleftherios Michailidis, and Steven J Coats, and Mahesh Kasthuri, and Nicolas Biteau, and Zahira Tber, and Maryam Ehteshami, and Raymond F Schinazi
Non-nucleoside reverse transcriptase inhibitors.
June 1996, BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation,
Franck Amblard, and Dharmeshkumar Patel, and Eleftherios Michailidis, and Steven J Coats, and Mahesh Kasthuri, and Nicolas Biteau, and Zahira Tber, and Maryam Ehteshami, and Raymond F Schinazi
Mass Spectrometric Characterization of HIV-1 Reverse Transcriptase Interactions with Non-nucleoside Reverse Transcriptase Inhibitors.
January 2016, Biological & pharmaceutical bulletin,
Franck Amblard, and Dharmeshkumar Patel, and Eleftherios Michailidis, and Steven J Coats, and Mahesh Kasthuri, and Nicolas Biteau, and Zahira Tber, and Maryam Ehteshami, and Raymond F Schinazi
The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
January 2013, Advances in pharmacology (San Diego, Calif.),
Franck Amblard, and Dharmeshkumar Patel, and Eleftherios Michailidis, and Steven J Coats, and Mahesh Kasthuri, and Nicolas Biteau, and Zahira Tber, and Maryam Ehteshami, and Raymond F Schinazi
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.
June 2003, AIDS (London, England),
Copied contents to your clipboard!